rss
Br J Ophthalmol 2004;88:48-53 doi:10.1136/bjo.88.1.48
  • Clinical science
    • Scientific reports

Bioavailability of fluorescein from a new drug delivery system in human eyes

  1. A Steinfeld1,
  2. A Lux1,
  3. S Maier2,
  4. R Süverkrüp2,
  5. M Diestelhorst1
  1. 1Department of Ophthalmology, University of Cologne, Germany
  2. 2Department of Pharmaceutical Technology, University of Bonn, Germany
  1. Correspondence to: A Steinfeld Department of Ophthalmology, University of Cologne, Germany; persteinfeldyahoo.com
  • Accepted 17 March 2003

Abstract

Aim: To assess the ocular bioavailability of fluorescein from a novel drug delivery system compared with one single preservative free eye drop.

Methods: Part A: In a randomised study 10 volunteers applied the lyophilisate to one eye and a conventional fluorescein eye drop to the fellow eye. Fluorophotometry was performed before and every 2 minutes up to 30 minutes after application in the cornea and anterior chamber. Part B: Another 10 volunteers applied each form of the application. Fluorophotometry was performed before, +2 minutes, and at +8, +10, +12 hours. The dose corresponding to a single fluorescein dose of the lyophilisate was 68 l μg fluorescein SE 0.17%.

Results: Part A: During the first 30 minutes after administration of the preservative free eye drop of 40 μg the corneal and anterior chamber concentration means were up to 16 times higher in eyes treated with the lyophilisate. Part B: 8–12 hours after application the mean fluorescein concentration in the cornea of the lyophilisate group was two times higher than at baseline. Eyes treated with eye drops had baseline values at +8, +10 and +12 hours.

Conclusion: A significantly better bioavailability was achieved in human eyes by using lyophilisate compared with the same dose from a conventional eye drop. Lyophilisates are a favourable alternative to conventional eye drops since they have no preservatives, higher long term stability, no pH adjustment, and easy handling.

Footnotes

  • R Süverkrüp and M Diestelhorst have a proprietary interest in the device.

This Article

  1. Abstract
  2. Full text
  3. PDF

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.